Shawn O’Connor
Chief Government Officer
Good afternoon or night because the case could also be, and welcome to Simulation Plus’ Investor Day. I would wish to thank every of you for becoming a member of us, our shareholders, analysts, companions and members of the broader life sciences neighborhood. Right now is a chance to step again from the day-to-day and consider the place we’re, the place the trade is headed and the place we’re positioning Simulations Plus for the long run.
Let me briefly define the agenda for our session. We’ll start with an summary of our imaginative and prescient, mission and values, adopted by firm highlights and a have a look at our historical past of progress as we strategy our thirtieth anniversary. We’ll then transfer by means of the main parts of our enterprise, the trade surroundings and the challenges and alternatives shaping drug growth, our software program product technique and financial yr ’26 roadmap, our scientific companies group, and we’ll conclude with a Q&A session.
This is a vital second for our trade. Biopharma is present process important transformation, the adoption of AI, the shift in direction of cloud-native scientific computation, the transfer away from animal testing and the rising reliance on model-informed drug growth. These adjustments are accelerating, and they’re redefining the means to develop secure, efficient therapies effectively. Additionally it is a defining second for Simulations Plus. We’re shaping our know-how, our companies and our working mannequin to satisfy the inflection level, strengthening our management whereas constructing the built-in ecosystem our purchasers want for future innovation. Right now, we’ll take a deeper dive into that ecosystem, our capabilities, our roadmap and the thrilling developments
